NAVB
Navidea Biopharmaceuticals Inc
Price:
0.08
USD
Volume:
1,030,238
United States | Biotechnology
No data available for this ticker
NAVB Probability of Bankruptcy
The Probability of Bankruptcy of Navidea Biopharmaceuticals Inc (NAVB) is 0% . This number represents the probability that NAVB will face financial distress in the next 24 months given its current fundamentals and market conditions.
Multiple factors are taken into account when calculating NAVB's probability of bankruptcy : Altman Z-score, Beneish M-score, financial position, macro environments, academic research about distress risk and more.
NAVB - Historical Solvency Measures
to of
Page of
NAVB - ESG ratings
ESG ratings are directly linked to the cost of capital and NAVB's ability to raise funding, both of which can significantly affect the probability of Navidea Biopharmaceuticals Inc going bankrupt.
ESG Score
0
Environment Score
0
Social Score
0
Governance Score
0
| Returns | |
| Historical Returns (5 day) | - |
| Historical Returns (MTD) | - |
| Historical Returns (YTD) | 500% |
| Historical Returns (13 week) | 500% |
| Historical Returns (26 week) | -40% |
| Historical Returns (52 week) | -76.93% |
| Efficiency | |
| Asset Turnover | 0.02 |
| Receiveable Turnover | 1.56 |
| Gross Margin | - |
| Operating Margin | - |
| Pretax Margin | - |
| Net Margin | - |
| Return on Asset (ROA) | -22.95 |
| Return on Equity (ROE) | -296.6 |
| Return on Investments (ROI) | -278.77 |
| Price Metrics | |
| Market Cap (M) | 0.1 |
| Enterprise Value (M) | -2.5 |
| 52 Week High | 0.13 |
| 52 Week Low | 0 |
| Beta | 1.62 |
| Average Volume (10 day) | 0.02 |
| Average Volume (3 month) | 0.01 |
| Price / Earnings (P/E) | - |
| Price / Sales (P/S) | 0.5 |
| Earnings | |
| EPS | -0.05 |
| Revenue CAGR (5 year) | -47.82% |
| Risk | |
| Current Ratio | 0.56 |
| Quick Ratio | 0.49 |
NAVB - Peer Comparisons
| Ticker | Company Name | Beta | Probability of Bankruptcy |
| a | |||
| SKYE | Skye Bioscience Inc | 2.06 | 18.2% |
| VRDN | Viridian Therapeutics Inc | 1.7 | 17% |